Penicillin susceptibility among invasive MSSA infections: a multicentre study in 16 Spanish hospitals
Resumen: Objectives: To determine the prevalence of penicillin susceptibility among MSSA causing bloodstream infections (BSIs) in 16 Spanish hospitals and to characterize the penicillin-susceptible MSSA (MSSA-PENS) isolates. Methods: A total of 1011 Staphylococcus aureus isolates were collected from blood cultures in 16 Spanish hospitals during 2018–19 (6–12 months) and their susceptibility to 18 antimicrobials was determined. The MSSA-PENS isolates were selected and examined by PCR to determine the presence of the blaZ gene, other resistance genes and the genes lukF/lukS-PV, eta, etb and tst. The immune evasion cluster (IEC) type was also analysed. All the MSSA-PENS isolates were submitted to S. aureus protein A (spa) typing and the clonal complexes (CCs) were assigned according to their spa type. Results: The prevalence of MSSA was 74.6% (754/1011) and 14.9% (151/1011) were MSSA-PENS-blaZnegative. MSSA-PENS-blaZnegative isolates (n = 151) were ascribed to 88 spa types and 11 CCs. The most frequent CCs were CC5 (35/151) and CC398 (25/151), with t002-CC5 and t571-CC398 being the most common lineages. Pan-susceptibility was identified in 117 of the 151 MSSA-PENS-blaZnegative isolates (77.5%). In the remaining isolates, erythromycin and clindamycin resistance was the most frequent resistance found, although tobramycin, ciprofloxacin, fusidic acid, mupirocin and/or tetracycline resistance was also detected. Thirty-eight MSSA-PENS-blaZnegative isolates were IEC negative and four isolates were Panton–Valentine leucocidin (‘PVL’) positive. Conclusions: A high penicillin susceptibility rate was detected among MSSA, opening therapeutic opportunities for BSIs. The emergence of new successful MSSA-PENS clones could be responsible for these data. The detection among MSSA-PENS-blaZnegative isolates of the clonal lineage CC398 or the absence of an IEC raises questions about their possible animal origin, requiring further analysis.
Idioma: Inglés
DOI: 10.1093/jac/dkab208
Año: 2021
Publicado en: The Journal of antimicrobial chemotherapy 76, 10 (2021), 2519–2527
ISSN: 0305-7453

Factor impacto JCR: 5.758 (2021)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 54 / 279 = 0.194 (2021) - Q1 - T1
Categ. JCR: INFECTIOUS DISEASES rank: 32 / 96 = 0.333 (2021) - Q2 - T2
Categ. JCR: MICROBIOLOGY rank: 39 / 138 = 0.283 (2021) - Q2 - T1

Factor impacto CITESCORE: 9.4 - Pharmacology, Toxicology and Pharmaceutics (Q1) - Medicine (Q1)

Factor impacto SCIMAGO: 1.495 - Infectious Diseases (Q1) - Pharmacology (medical) (Q1) - Microbiology (medical) (Q1)

Financiación: info:eu-repo/grantAgreement/ES/AEI-FEDER-ICS/SAF2016–76571-R
Financiación: info:eu-repo/grantAgreement/ES/AEI/PID2019-106158RB-I00
Tipo y forma: Artículo (PostPrint)
Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)

Derechos Reservados Derechos reservados por el editor de la revista


Exportado de SIDERAL (2023-05-18-15:14:43)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos



 Registro creado el 2022-07-11, última modificación el 2023-05-19


Postprint:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)